Read, Watch or Listen

Pfizer raised its full-year adjusted profit guidance to $2.90-$3.10 per share, exceeding Wall Street expectations. Second-quarter earnings per share reached 78 cents (adjusted), surpassing the anticipated 58 cents, with revenue hitting $14.65 billion. This positive performance follows cost-cutting measures and despite President Trump's pressure to lower drug prices and potential tariffs. The company maintains its 2025 revenue forecast of $61-$64 billion, factoring in existing tariffs and potential price adjustments.

Prepared by Christopher Adams and reviewed by editorial team.